1042 The dual function of the adenosine pathway in the liposarcoma tumor microenvironment
Jacqueline Oliva, Younghee Lee, R. Rodriguez, Katarzyna Tomczak, Davis R. Ingram, Xiaofang Zhou, Vinod Ravi, Anthony P. Conley, John H. Livingston, Joseph A. Ludwig, Neeta Somaiah, Cara HaymakerRegular2022 · DOI
Researchers have uncovered a surprising "double agent" role for the adenosine pathway in liposarcoma. While the A2A receptor (A2AR) is linked to T-cell exhaustion and mitochondrial failure, the protein CD73—usually considered a partner in immunosuppression—actually identifies the T-cells most capable of robust growth and expansion for potential therapy.
What Problem Does This Paper Address?
Liposarcoma (LPS), a cancer of the fatty tissue, is notoriously resistant to standard "checkpoint inhibitor" immunotherapies like anti-PD1. While combining treatments (anti-CTLA4 + anti-PDL1) shows more promise, researchers are still trying to figure out why the immune system struggles to stay active within these tumors.
A major suspect is the adenosine pathway. In many cancers, the enzyme CD73 breaks down chemicals into adenosine, which then binds to the A2A receptor (A2AR) on T-cells, effectively putting them to sleep. However, recent biology suggests CD73 might also mark long-lived, high-performance "memory" T-cells. This paper investigates this paradox: is the adenosine pathway a pure villain in liposarcoma, or does it play a more nuanced role in how tumor-infiltrating lymphocytes (TILs) survive and function?
Methods
The study analyzed 41 surgically resected liposarcoma samples using a multi-pronged approach:
Phenotyping: Flow cytometry was used to map out the "immune landscape," looking for markers like CD73, A2AR, PD-1, and LAG3.
TIL Expansion: The team used the "TIL 3.0" protocol to see if they could grow the patient's own immune cells in a lab setting—a critical step for adoptive cell therapy.
Metabolomics: They quantified actual adenosine concentrations within the tumor tissue.
Functional & Metabolic Assays: Expanded T-cells were tested for their ability to produce Interferon-gamma (IFN-g) and monitored for metabolic health, specifically looking at mitochondrial mass and reactive oxygen species (ROS) production.
Datasets
The study relied on a primary clinical dataset of 41 liposarcoma samples collected at the University of Texas MD Anderson Cancer Center. It also draws context from the MDACC clinical trial NCT02815995, which previously noted changes in CD73 and PD-1 expression during combination immunotherapy.
Key Insights and Ideas
The Great Heterogeneity: The tumors were incredibly diverse. Some were packed with immune cells (88% CD45+), while others were "cold" deserts. Adenosine levels also fluctuated wildly (0 to 84 nmol/g), yet surprisingly, high adenosine levels didn't always correlate with a "tired" immune phenotype.
A Functional Dichotomy: The most striking finding was that CD73 and A2AR are rarely found on the same cell. They seem to represent two different sides of the immune story in liposarcoma.
CD73 as a Growth Marker: Contrary to the initial hypothesis that the adenosine pathway would hinder TILs, cells expressing CD73 were actually more likely to expand successfully in the lab. This suggests CD73 might be a marker of T-cell fitness or "stemness" in this specific cancer type.
A2AR as the "Brake": While CD73 was linked to growth, A2AR was the clear culprit for dysfunction. High A2AR expression correlated with mitochondrial "burnout" and a reduced ability to kill tumor cells.
Key Results
Expansion Success: TILs were successfully expanded in 50% of the cases (24/41).
Statistical Significance: The presence of CD8+CD73+ T-cells was significantly higher in samples that successfully expanded ($p=0.041$).
Metabolic Link: IFN-gamma production (a sign of an active immune response) was directly tied to the T-cells' intrinsic metabolic state, specifically their mitochondrial mass.
Expression Ranges: CD73 expression on CD8+ T-cells ranged from 0% to 34%, while A2AR expression on expanded CD8+ cells reached as high as 87.6%.
Limitations and Future Work
The authors acknowledge that while they've found a strong correlation between CD73 and TIL expansion, the sample size for the deep metabolic profiling was small ($n=8$).
The "aha moment" here—that CD73 might be a "good guy" marker for cell therapy while A2AR remains the target for inhibition—opens a new door for treatment. Future work will likely focus on whether we can selectively block A2AR to prevent T-cell exhaustion without accidentally harming the robust CD73+ T-cell populations that are best suited to fight the tumor.
Summary updated
Abstract
<h3>Background</h3> Single agent anti-PD1 therapy has shown limited clinical benefit in liposarcoma, but combination with anti-CTLA-4 demonstrated a higher response rate.<sup>1-3</sup> In the MDACC study NCT02815995, combining anti-CTLA4 and anti-PDL1 across multiple soft-tissue sarcomas increased CD73, PD-1, and OX40 expression in T cells early on treatment. The adenosine pathway, which includes CD73 and the A2A receptor, induces immunosuppression<sup>4,5</sup> and protects from antitumoral responses.<sup>6, 7</sup> This pathway is related to immune therapy resistance<sup>8-11</sup>, metastasis, and poor prognosis.<sup>12-15</sup> Conversely, CD73+ T cells have long-lived memory and higher proliferation and survival, suggesting a dual role of the pathway.<sup>16-18</sup> We hypothesized that adenosine would negatively correlate with TIL expansion and function. <h3>Methods</h3> Surgically resected liposarcoma samples (n=41), are divided for fresh tissue phenotyping by flow cytometry, TIL expansion, and quantification of tissue adenosine, cytokines, and adipokines. The phenotypic analysis included: CD73, A2aR, PD-1, Tim3, CTLA-4, LAG3, OX40, ICOS and 41BB markers. TIL 3.0 expansion protocol<sup>19</sup> was performed, and expanded TIL were assessed for cytotoxicity by IFN-g production and metabolic state (ROS, mitochondrial activity) by flow cytometry. <h3>Results</h3> We found high heterogeneity in the frequency of CD45+ cells (0-88.3%), CD4+ and CD8+ TIL infiltrate, and expression of PD-1 (0.66-59.60% and 0.99-76.6% respectively), CD73 (CD4+ 0- 40.97%, CD8+ 0-34.04%), and A2AR (mean CD4+ 0-0.6%, CD8+ 0-17.96%), with no co-expression of CD73 and A2AR. Interestingly adenosine concentration was highly variable (0-84.05 nmol/g tissue) but did not correlate with TIL phenotype or tissue cytokines. Tumors were rich in growth factors and chemokines but lacked a pro-inflammatory profile. The success of TIL expansion was 50% (n=24 cases) in samples with a count of 300 CD3+ events in the fresh tissue by flow analysis. The frequency of CD8+CD73+ TIL was significantly higher in cases with successful TIL expansion (p=0.041). The expanded TIL phenotype showed CD73 expression (range: CD4+ 0.67-29 % and CD8+ 0.85-13.9%) and upregulation of A2AR (range: 0.2-15.40% and 1.44-87.6%). IFN-g production was related to intrinsic metabolic profiles by mitochondrial mass and ROS production (n=8). <h3>Conclusions</h3> A heterogeneous adenosine landscape was found in liposarcoma. A2AR but not CD73 correlated with mitochondrial dysfunction and reduced cytotoxicity. Conversely CD73+ TIL were more likely to expand. Our results indicate a dichotomy in two key members in the adenosine pathway in liposarcoma and suggest that CD73 might play a positive role in TIL function. <h3>Acknowledgements</h3> Patients and their families. CCSG Metabolomics Core (Grant P30CA016672) Philanthropy support provided by a generous donation by the William Oates family <h3>References</h3> Klaver Y, <i>et al</i>. Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes. <i>J Immunother Cancer</i> 2020;<b>8</b>(2). Livingston JA, <i>et al</i>. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. <i>Sci Rep</i>, 2017;<b>7</b>(1):11836. D’Angelo SP, <i>et al</i>. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncol</i> 2018;<b>19</b>(3):416–426. Jin D, <i>et al</i>. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. <i>Cancer Res</i> 2010;<b>70</b>(6):2245–55. Allard B, <i>et al</i>. The adenosine pathway in immuno-oncology. <i>Nat Rev Clin Oncol</i> 2020;<b>17</b>(10):611–629. Mastelic-Gavillet, B., <i>et al</i>., Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells. <i>J Immunother Cancer</i> 2019;<b>7</b>(1):257. Ohta A, <i>et al</i>. A2A adenosine receptor protects tumors from antitumor T cells. <i>Proc Natl Acad Sci U S A</i> 2006;<b>103</b>(35):13132–7. Zhou L, <i>et al</i>. The distinct role of CD73 in the progression of pancreatic cancer. <i>J Mol Med (Berl)</i> 2019;<b>97</b>(6):803–815. Wu R, <i>et al</i>. Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro. <i>Oncol Rep</i> 2016;<b>35</b>(3):1750–6. Chen S <i>et al</i>. CD73 expression on effector T cells sustained by TGF-beta facilitates tumor resistance to anti-4-1BB/CD137 therapy. <i>Nat Commun</i> 2019;<b>10</b>(1):150. Cekic C <i>et al</i>. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. <i>Cancer Res</i> 2014;<b>74</b>(24):7250–9. Turcotte M <i>et al</i>. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. <i>Cancer Res</i> 2015;<b>75</b>(21):4494–503. Panigrahi S, <i>et al</i>., CD8(+) CD73(+) T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue. <i>Eur J Immunol</i> 2020;<b>50</b>(12):2055–2066. Gao Z.W, <i>et al</i>. CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity. <i>BMC Cancer</i> 2017;<b>17</b>(1):135. Koszalka P, <i>et al</i>. Targeted disruption of cd73/ecto-5’-nucleotidase alters thromboregulation and augments vascular inflammatory response. <i>Circ Res</i> 2004;<b>95</b>(8):814–21. Capone M, <i>et al</i>. Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.<i> J Transl Med</i> 2020;<b>18</b>(1):121. Rosemblatt MV, <i>et al</i>. Ecto-5’-Nucleotidase (CD73) Regulates the Survival of CD8+ T Cells. <i>Front Cell Dev Biol</i> 2021;<b>9</b>:647058. Fang F, <i>et al</i>. The cell-surface 5’-nucleotidase CD73 defines a functional T memory cell subset that declines with age. <i>Cell Rep</i> 2021;<b>37</b>(6):109981. Tavera RJ. <i>et al</i>. Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.<i> J Immunother</i> 2018;<b>41</b>(9):399–405. <h3>Ethics Approval</h3> This study was written and conducted in accordance with the principles from the Declaration of Helsinki. Written informed consent was provided by all study participants or their legal representatives. The study was approved by the University of Texas MD Anderson Cancer Center‘s Institutional Review Board.
BibTeX
@inproceedings{oliva2022dual,
author = {Jacqueline Oliva and Younghee Lee and R. Rodriguez and Katarzyna Tomczak and Davis R. Ingram and Xiaofang Zhou and Vinod Ravi and Anthony P. Conley and John H. Livingston and Joseph A. Ludwig and Neeta Somaiah and Cara Haymaker},
title = {{1042 The dual function of the adenosine pathway in the liposarcoma tumor microenvironment}},
booktitle = {Regular},
year = {2022},
doi = {10.1136/jitc-2022-sitc2022.1042},
}